Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma

A Ingels, R Campi, U Capitanio, D Amparore… - Nature Reviews …, 2022 - nature.com
Standard-of-care management of renal cell carcinoma (RCC) indisputably relies on surgery
for low-risk localized tumours and systemic treatment for poor-prognosis metastatic disease …

Management of metastatic clear cell renal cell carcinoma: ASCO guideline

WK Rathmell, RB Rumble… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To provide recommendations for the management of patients with metastatic
clear cell renal cell carcinoma (ccRCC). METHODS An Expert Panel conducted a systematic …

French AFU Cancer Committee Guidelines-update 2022-2024: management of kidney cancer

P Bigot, P Barthelemy, R Boissier, ZE Khene… - Progrès en Urologie, 2022 - Elsevier
Aim To update the recommendations for the management of kidney cancers. Methods A
systematic review of the literature was conducted from 2015 to 2022. The most relevant …

The selection for cytoreductive nephrectomy (SCREEN) score: improving surgical risk stratification by integrating common radiographic features

EJ Abel, VA Master, PE Spiess, JD Raman… - European Urology …, 2024 - Elsevier
Background Careful patient selection is critical when considering cytoreductive nephrectomy
(CN) for metastatic renal cell carcinoma (mRCC) but few studies have investigated the …

Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC

A Das, DD Shapiro, JK Craig, EJ Abel - Nature Reviews Urology, 2023 - nature.com
Cytoreductive nephrectomy became accepted as standard of care for selected patients with
metastatic renal cell carcinoma (mRCC) because of improved survival observed in patients …

Cytoreductive nephrectomy and metastatic renal cell carcinoma: state of the art and future perspectives

L Napolitano, C Manfredi, L Cirillo, GM Fusco… - Medicina, 2023 - mdpi.com
In the past decades, several treatments have been proposed for the management of
metastatic renal cell carcinoma (mRCC). Among these, cytoreductive nephrectomy (CN) …

Pathological outcomes of patients with advanced renal cell carcinoma who receive nephrectomy following immunotherapy

J Panian, A Saidian, K Hakimi, A Ajmera… - The …, 2024 - academic.oup.com
Background Even though cytoreductive nephrectomy (CN) was once the standard of care for
patients with advanced renal cell carcinoma (RCC), its role in treatment has not been well …

The evolving landscape of cytoreductive nephrectomy in metastatic renal cell carcinoma

H Studentova, M Spisarova, A Kopova, A Zemankova… - Cancers, 2023 - mdpi.com
Simple Summary For a significant period of time, the removal of the primary tumor termed
cytoreductive nephrectomy has been considered the standard of care in patients with …

Treatment options for de novo metastatic clear-cell renal cell carcinoma: current recommendations and future insights

D Benamran, L Albiges, A Bex, G Giannarini… - European Urology …, 2022 - Elsevier
This clinical case–based discussion focuses on a 73-yr-old man diagnosed with
intermediate-risk oligometastatic clear-cell renal cell carcinoma (RCC) and treated with …

[HTML][HTML] Cytoreductive nephrectomy in the age of immunotherapy-based combination treatment

SH Song, S Lee - Investigative and clinical urology, 2023 - ncbi.nlm.nih.gov
Renal cell carcinoma (RCC) displays a wide spectrum of oncological prognosis and clinical
behavior, and is noted for its generally poor outcome in metastatic settings. However, the …